Free weekly newsletter

Get the free weekly executive digest

The new leadership moves, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.

Weekly Digest

New leadership moves, summarized for you

Straight to Inbox

No login, no app to check — it comes to you

Leadership Trends

See who's moving and how much in your market

No credit card required Weekly executive digest

Reunion Neuroscience Inc. Appoints Mark Pollack, M.D. As Chief Medical Officer

PRIVATESep 10, 2024•almost 2 years ago

Position

Chief Medical Officer

Company

Reunion Neuroscience Management

Mark Pollack

MorristownBiotechnologyHealth Care

Description

Reunion Neuroscience Inc. announced the appointment of Mark Pollack as Chief Medical Officer, who will be replacing Dr. Robert Alexander in the role

Company Information

Company

Reunion Neuroscience Management

Location

1 HIGH STREET COURT

Morristown, New Jersey, United States

About

Reunion Neuroscience is a clinical-stage biopharmaceutical company committed to revolutionizing the treatment of underserved mental health disorders through the advancement of next-generation psychedelic therapeutic solutions. In August of 2023, Reunion Neuroscience became a private company and in May 2024, the Company completed a Series A financing co-led by MPM BioImpact and Novo Holdings. Reunion is actively investigating the use of its lead product candidate, RE104, in postpartum depression and adjustment disorder, as well as in additional neuropsychiatric indications where there remains a significant unmet need that is not addressed by the current standard of care.

Related People

Suggested for you

Choose your plan to reveal verified contacts

Predictive Intelligence

Strategic

ML-powered predictions for Reunion Neuroscience Management's next move

Learn about Strategic plan

Executive Insights

Based on hiring data

New executive impact window

87% of new executives make significant technology decisions within first 100 days

Budget influence

C-level executives control 73% of technology spending decisions

Transformation catalyst

65% of new senior hires launch digital transformation initiatives

Vendor review timeline

New executives typically review existing vendors within 6 months